Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.49 | 8.29 | 10.59 | 7.44 | 5.87 | 5.80 | 3.50 | 2.92 | 4.31 | 3.21 | 3.60 | 2.41 |
| Expenses | 9.66 | 8.16 | 9.38 | 6.13 | 7.20 | 6.43 | 10.08 | 6.24 | 4.19 | 3.64 | 3.37 | 4.57 |
| Operating Profit | -2.17 | 0.13 | 1.21 | 1.31 | -1.33 | -0.63 | -6.58 | -3.32 | 0.12 | -0.43 | 0.23 | -2.16 |
| OPM % | -28.97% | 1.57% | 11.43% | 17.61% | -22.66% | -10.86% | -188.00% | -113.70% | 2.78% | -13.40% | 6.39% | -89.63% |
| Other Income | 0.14 | 0.00 | 0.27 | 0.16 | 0.12 | 0.17 | 0.87 | 0.01 | 0.02 | 0.02 | 0.17 | 0.10 |
| Interest | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.12 | 0.13 | 0.13 | 0.15 | 0.13 |
| Profit before tax | -2.14 | 0.01 | 1.16 | 1.36 | -1.33 | -0.58 | -5.84 | -3.43 | 0.01 | -0.54 | 0.25 | -2.19 |
| Tax % | -9.35% | 0.00% | -3.45% | 30.15% | 0.00% | 1.72% | -29.62% | 0.00% | 0.00% | 1.85% | 244.00% | 0.00% |
| Net Profit | -1.94 | 0.01 | 1.20 | 0.95 | -1.33 | -0.59 | -4.11 | -3.43 | 0.02 | -0.54 | -0.36 | -2.19 |
| EPS in Rs | -1.92 | 0.01 | 1.19 | 0.94 | -1.32 | -0.58 | -4.07 | -3.40 | 0.02 | -0.53 | -0.36 | -2.17 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 14.05 | 13.53 |
| Expenses | 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 24.50 | 17.44 | 15.77 |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -1.89 | -3.39 | -2.24 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -8.36% | -24.13% | -16.56% |
| Other Income | 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | -4.02 | 0.22 | 0.31 |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.52 | 0.54 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -3.69 | -2.47 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | -16.26% | |
| Net Profit | 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -3.08 | -3.07 |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -3.05 | -3.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | -24% | -32% | -25% | ||
| Compounded Profit Growth | % | % | % | 68% | ||
| Stock Price CAGR | 2% | -29% | -30% | -43% | ||
| Return on Equity | % | 10% | -7% | -14% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 | 10.57 |
| Borrowings | 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 | 0.50 |
| Other Liabilities | 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 | 3.16 |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 24.33 |
| Fixed Assets | 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.54 | 2.26 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 3.39 | 0.26 | 0.26 |
| Other Assets | 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 27.33 | 22.96 | 21.81 |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 24.33 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.10 | 0.23 | -15.18 | 1.83 | 8.26 | -1.56 | 4.85 | -9.82 | -2.45 |
| Cash from Investing Activity | 0.00 | -0.02 | -0.01 | -0.31 | -1.13 | -4.28 | -1.79 | 3.07 | -0.24 |
| Cash from Financing Activity | 0.09 | 0.07 | 16.36 | 3.99 | 1.30 | -2.15 | -1.17 | 0.24 | 0.00 |
| Net Cash Flow | -0.01 | 0.28 | 1.17 | 5.51 | 8.43 | -7.99 | 1.90 | -6.51 | -2.69 |
| Free Cash Flow | -0.10 | 0.22 | -15.42 | 1.52 | 8.06 | -2.34 | 4.79 | -9.88 | -2.69 |
| CFO/OP | -143% | 51% | -602% | 53% | 137% | 37% | -713% | 520% | 72% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 | 67.54 |
| Inventory Days | 91.25 | 19.70 | 0.00 | ||||||
| Days Payable | 511.00 | 192.66 | |||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 | 67.54 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 | 382.15 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% | -16.67% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% | 16.43% |
| Public | 83.57% | 83.57% | 83.58% | 83.57% | 83.57% | 83.58% | 83.56% | 83.57% | 83.57% | 83.58% | 83.59% | 83.57% |
| No. of Shareholders | 35,728 | 34,511 | 33,371 | 32,833 | 31,838 | 31,482 | 31,182 | 30,512 | 30,174 | 29,825 | 29,596 | 29,368 |
Fundamentals
Market Cap₹ 6.06 Cr.
Current Price₹ 6.00
Book Value₹ 20.5
ROCE-16.7 %
ROE-14.2 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-25%
Compounded Profit Growth (TTM)68%
Consolidated figures.
Valuation
Market capRs 6 Cr
Enterprise valueRs 3 Cr
Price to book0.27x
Price to sales0.45x
EV / sales0.26x
Earnings yield-50.66%
P/B, 3-year average0.59x
P/E, 5-year average14.42x
P/B, 5-year average1.29x
Profitability
Operating margin (excl. other income)-8.36%
Operating margin (incl. other income)-26.14%
EBITDA margin-14.26%
Pre-tax margin-18.26%
Net profit margin-22.69%
Net margin, latest quarter-90.87%
ROE-22.72%
ROCE-28.43%
ROA-17.11%
ROE, 3-year average-13.83%
ROCE, 3-year average-15.06%
ROA, 3-year average-10.06%
ROE, 5-year average5.86%
ROCE, 5-year average1.37%
ROA, 5-year average0.36%
ROIC (approx.)-9.68%
Tax rate20.50%
Other income / net worth-17.59%
Growth
Sales growth (latest year)-36.98%
Sales CAGR, 3 years-29.79%
Sales CAGR, 5 years-1.18%
Sales growth QoQ-33.06%
Sales growth YoY (latest quarter)-17.47%
Per share
EPS (TTM)Rs -3.04
EPS (latest year)Rs -5.03
EPS (latest quarter)Rs -2.17
EPS, 3-year averageRs -3.12
EPS, 5-year averageRs 0.66
Book value per shareRs 22.63
Sales per shareRs 13.40
Cash flow per shareRs -9.72
Free cash flow per shareRs -2.66
Efficiency
Asset turnover0.88x
Fixed asset turnover8.90x
Debtor days68 days
Debtors turnover5.36x
Creditor days193 days
Cash conversion cycle68 days
Working capital days382 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 3 Cr
Net debtRs -3 Cr
Debt to equity0.01x
Owners' fund to total sources88.74%
Debt to assets0.93%
Cash flow
Cash from Operating Activity (latest year)Rs -10 Cr
Cash from Investing Activity (latest year)Rs 3 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Net Cash Flow (latest year)Rs -7 Cr
Free cash flow (latest year)Rs -3 Cr
Statement figures
Net sales (TTM)Rs 14 Cr
Net sales (latest year)Rs 23 Cr
Sales (latest quarter)Rs 2 Cr
Operating profit excl. other income (latest year)Rs -2 Cr
Operating profit (latest quarter)Rs -2 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -2 Cr
PBDT (TTM)Rs -2 Cr
Profit before tax (TTM)Rs -2 Cr
Tax (latest year)Rs -1 Cr
Net profit (TTM)Rs -3 Cr
Net profit (latest year)Rs -5 Cr
Net profit (latest quarter)Rs -2 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Cost of goods sold (latest year)Rs 1 Cr
Total expenditure (latest year)Rs 24 Cr
Total income (latest year)Rs 19 Cr
Share capitalRs 10 Cr
ReservesRs 13 Cr
Shareholders' fundsRs 23 Cr
Total assetsRs 26 Cr
Net blockRs 3 Cr
InvestmentsRs 0 Cr
ReceivablesRs 4 Cr
Other liabilitiesRs 3 Cr
Shares outstanding (crore)1.01
Ownership
Promoter holding16.43% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 0.27 is at the 2th percentile (median 1.49).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524752 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -3.2% | -2.8% | -0.4 pts |
| 1 month | +6.2% | -6.8% | +13.0 pts |
| 3 months | -10.6% | -7.6% | -3.0 pts |
| 3 years | -65.7% | +14.2% | -79.9 pts |
| 5 years | -81.2% | +27.9% | -109.1 pts |
Red flags
F-score 1 of 8| explain | High accruals Profit exceeded operating cash by 18% of total assets in 2026 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹2 Cr -17.5% vs Jun 2025.
Net loss ₹2 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Decipher Labs Ltd?
Decipher Labs Ltd (524752) has a market capitalisation of Rs 6.06 Cr. at the 2026-10-01 close.
What were Decipher Labs Ltd's latest quarterly results?
In the Jun 2026 quarter, Decipher Labs Ltd sales was Rs 2 Cr (-17.5% vs Jun 2025) with a net loss of Rs 2 Cr.